PTC Therapeutics

News

Bottles of prescription medicine in a pile. This collection of pill bottles is symbolic of the many medications senior adults and chronically ill people take.

PTC shares soar after SMA drug data impresses market

After failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on verge of a breakthrough in the SMA field.

News

Pharma collaborates to improve chances of NICE backing Duche...

Project will initially focus on DMD but could benefit other rare diseases

News

PTC Therapeutics fails to convince FDA panel about DMD drug

FDA advisers have voted against approval for PTC Therapeutics’ Duchenne drug Translarna because of doubts about its efficacy.

News

FDA reviewers slam PTC's Duchenne drug ahead of meeting

FDA staff not persuaded by patchy clinical trial evidence for Translarna.

News

Sarepta announces Allergan veteran as next CEO

Sarepta has announced former Allergan president Doug Ingram will be its new CEO.

News

Outrage over Duchenne drug price reinflamed by PTC's $35,000...

Families affected by the rare muscle wasting disease Duchenne muscular dystrophy will still have to pay a huge premium for Emflaza, a newly-approved drug based on an old steroid that helps

PTC shares soar after SMA drug data impresses market

Pharma collaborates to improve chances of NICE backing Duche...

PTC Therapeutics fails to convince FDA panel about DMD drug

FDA reviewers slam PTC's Duchenne drug ahead of meeting

Sarepta announces Allergan veteran as next CEO

Outrage over Duchenne drug price reinflamed by PTC's $35,000...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

PTC Therapeutics

Editor's Picks